Pernix Therapeutics offers $4.9M for CMO Great Southern Laboratories

With a $4.9 million offer on the table, pharma company Pernix Therapeutics ($PTX) will acquire Houston CMO Great Southern Laboratories in deal that should be closed before month's end, according to a company statement. Once finalized, Pernix hopes the acquisition will improve its profit margins on generics, while laying the foundation for developing future over-the-counter and prescription products, according to the pharma company. Great Southern earns its keep by manufacturing liquids, tablets, capsules, ointments and creams, generating about $12 million in revenues for fiscal 2011. Statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.